Login to Your Account

Strategia starts phase I of Fujifilm cancer candidate

By Michael Fitzhugh
Staff Writer

Friday, February 19, 2016

Strategia Therapeutics Inc., of Boston, has started a U.S.-based phase I trial of the antimetabolite agent FF-10502 in patients with advanced solid tumor cancers and lymphoma.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription